Table 1.
Summary of biostatistical and bioinformatic analyses for individual treatments – Acute Control vs Acute treatment and Chronic Control vs Chronic Treatment. GO – gene ontology terms.
| Acute v Chronic | Acute treatment v Acute Control | Chronic treatment v Chronic Control | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Control | Isoflurane | Ketamine | Propofol | Isoflurane | Ketamine | Propofol | Isoflurane | Ketamine | Propofol | |
| Total Significant genes (% of genes examined) | 18 (0.08%) | 17 (0.07%) | 9 (0.04%) | 5 (0.02%) | 27 (0.12%) | 34 (0.15%) | 24 (0.1%) | 18 (0.08%) | 18 (0.08%) | 15 (0.06%) |
| Significant Increase (% significant genes) | 6 (33.33%) | 12 (70.59%) 11 coding, 1 unassigned | 4 (44.44%) | 2 (40%) | 16 (59.26%) 14 coding, 1 non-coding, 1 unassigned | 16 (47.06%) 16 coding | 14 (58.33%) | 9 (50%) 8 coding, 1 non-coding | 7 (38.89%) 7 coding | 6 (40%) 4 coding, 2 multi complex |
| Significant decrease (% significant genes) | 12 (66.67%) | 5 (29.41%), 5 coding | 5 (55.56%) | 3 (60%) | 11 (40.74%) 11 coding | 18 (52.94%) 17 coding, 1 non-coding | 10 (41.67%) | 9 (50%) 9 coding | 11 (61.11%) 11 coding | 9 (60%) 9 coding |
| Maximum significant fold increase | 4.01 | 246.3 | 2.35 | 2.47 | 4.86 | 4.75 | 6.13 | 3.14 | 3.03 | 4.7 |
| Maximum significant fold decrease | 258.71 | 2.28 | 2.4 | 2.14 | 230.12 | 125.39 | 259.24 | 4.37 | 4.39 | 19.01 |
| Significant Functional GO categories | 11 | 1 | 0 | 0 | 26 | 10 | 20 | 64 | 7 | 11 |